Kaiwen Wang
Assistant Professor of Data Science
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2026
Extracting meaningful biological signals from Cytometry by time-of-flight (CyTOF) data remains challenging due to heterogeneity, data characteristics, and the presence of various technical artifacts. Current analysis workflows typically rely on task-specific tools assembled into pipelines, which often make inconsistent distributional assumptions and fail to fully leverage the structure of the data. We present CytoOne, a unified probabilistic framework tailored for CyTOF data that integrates batch correction, differential analysis, and visualization within a single model. CytoOne is built upon a Bayesian hierarchical architecture inspired by Nouveau Variational Autoencoders (NVAE) and employs a novel quasi zero-inflated softplus-normal (QZIPN) likelihood to flexibly model the sparse and noisy nature of CyTOF measurements. We demonstrate via qualitative and quantitative evaluations that CytoOne effectively approximates both marginal and joint distributions of CyTOF data, removes batch-specific artifacts, enables fine-grained differential expression analysis, and facilitates interpretable embeddings for exploratory analysis.
Year:
2025
With the rise of large-scale genomic studies, large gene lists targeting important diseases are increasingly common. While evaluating each study individually gives valuable insights on specific samples and study designs, the wealth of available evidence in the literature calls for robust and efficient meta-analytic methods. Crucially, the diverse assumptions and experimental protocols underlying different studies require a flexible but rigorous method for aggregation. To address these issues, we propose BiGER, a fast and accurate Bayesian rank aggregation method for the inference of latent global rankings. Unlike existing methods in the field, BiGER accommodates mixed gene lists with top-ranked and top-unranked genes as well as bottom-tied and missing genes, by design. Using a Bayesian hierarchical framework combined with variational inference, BiGER efficiently aggregates large-scale gene lists with high accuracy, while providing valuable insights into source-specific reliability for researchers. Through both simulated and real datasets, we show that BiGER is a useful tool for reliable meta-analysis in genomic studies.
Year:
2025
Year:
2024
The interaction between antigens and antibodies (B cell receptors, BCRs) is the key step underlying the function of the humoral immune system in various biological contexts. The capability to profile the landscape of antigen-binding affinity of a vast number of BCRs will provide a powerful tool to reveal novel insights at unprecedented levels and will yield powerful tools for translational development. However, current experimental approaches for profiling antibody-antigen interactions are costly and time-consuming, and can only achieve low-to-mid throughput. On the other hand, bioinformatics tools in the field of antibody informatics mostly focus on optimization of antibodies given known binding antigens, which is a very different research question and of limited scope. In this work, we developed an innovative Artificial Intelligence tool, Cmai, to address the prediction of the binding between antibodies and antigens that can be scaled to high-throughput sequencing data. Cmai achieved an AUROC of 0.91 in our validation cohort. We devised a biomarker metric based on the output from Cmai applied to high-throughput BCR sequencing data. We found that, during immune-related adverse events (irAEs) caused by immune-checkpoint inhibitor (ICI) treatment, the humoral immunity is preferentially responsive to intracellular antigens from the organs affected by the irAEs. In contrast, extracellular antigens on malignant tumor cells are inducing B cell infiltrations, and the infiltrating B cells have a greater tendency to co-localize with tumor cells expressing these antigens. We further found that the abundance of tumor antigen-targeting antibodies is predictive of ICI treatment response. Overall, Cmai and our biomarker approach filled in a gap that is not addressed by current antibody optimization works nor works such as AlphaFold3 that predict the structures of complexes of proteins that are known to bind.
Year:
2024
Year:
2023
Collaborators (4)
David Gerber
Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences
University of Texas Southwestern Medical Center
Xinlei Wang
Professor
The University of Texas at Arlington
Tao Wang
The University of Texas MD Anderson Cancer Center
Guanghua Xiao
-
Make your next move.
Prepare your application
Review drafts before you send them.